ESCAT: a step in the right direction

Affiliations

¹ School of Medicine, Vanderbilt University, Nashville, Vanderbilt University, Nashville, USA.
² Departments of Medicine (Division of Hematology/Oncology) and Biomedical Informatics, Vanderbilt University, Nashville, USA. Electronic address: jeremy.warner@vanderbilt.edu.

Comment

A J Silver et al. Ann Oncol. 2018.

. 2018 Nov 1;29(11):2266-2267.

doi: 10.1093/annonc/mdy409.

¹ School of Medicine, Vanderbilt University, Nashville, Vanderbilt University, Nashville, USA.
² Departments of Medicine (Division of Hematology/Oncology) and Biomedical Informatics, Vanderbilt University, Nashville, USA. Electronic address: jeremy.warner@vanderbilt.edu.

No abstract available

Comment on

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L. Mateo J, et al. Ann Oncol. 2018 Sep 1;29(9):1895-1902. doi: 10.1093/annonc/mdy263. Ann Oncol. 2018. PMID: 30137196 Free PMC article.

1. Mateo J, Chakravarty D, Dienstmann R. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 2018; 29(9): 1895–1902. - PMC - PubMed
1. Meador CB, Micheel CM, Levy MA. et al. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res 2014; 20(9): 2264–2275. - PMC - PubMed
1. Kobayashi S, Boggon TJ, Dayaram T. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352(8): 786–792. - PubMed
1. Slamon DJ, Leyland-Jones B, Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783–792. - PubMed